Member Info for technick

dream, careful, you're revelling in others misfortune

Ha, as I've posted many times here, lives saved is worth my investment, I support the Company in it's goal to save lives, as this happens the share price will rise, I'm not worried or concerned about delays to a technical program.... dream on the other hand isn't invested but tries to knock a business trying to make a difference.... gotta ask yourself who's values have more integrity?

JH I agree, the study was outrageous, and they didn't even continually test the participants, it seems to be all subjectively based 'symptoms' suggesting they wanted an easy barrier for their claims

We are bored, but not of the Company

I can’t believe the egos of some on here.

We’re in the middle of a pandemic with many people dying each day. GDR have developed a great set of products aimed at diagnosing people and it’s not their fault they are locked into an approvals cycle. They have orders lined up.

Don’t knock those trying to make a difference, and if you’re not invested but post continually then you really do have to look hard at your motives.

The RNS was as expected, no news is no news. Orders being lined up. Approvals in process and feedback this month suggesting all still moving through.

While there has been excellent sales funnel progression since the summer, there have been no material deliverable contracts to date as further key registrations have not yet been achieved. We have also focused commercially on the larger, more strategic opportunities that by their nature take longer to come to fruition. These are higher risk, but higher reward. We remain optimistic about the full potential of the test, and our pipeline of sales opportunities for 96 SARS-CoV-2 test includes a supply opportunity to a Ministry of Health of European country which the company is engaged with directly. This opportunity is at an advanced stage but may of course not conclude successfully. If we are successful the total revenue expectation is for low double digit millions of pounds in the first quarter of the new calendar year and we do not expect additional approval processes. We expect that our high throughput test will make a significant contribution to revenue over the coming periods. Finally, new relationships in new markets, such as with Beckman Coulter are presenting new and unique revenue opportunities for the Company.

For all the real GDR investors here, tomorrow will bring clarity...

... we know the results to June will be announced this week and we have a presentation from DB. I hope he will outline the broader strategy the business is following in terms of sales channels and what triggers those and why those channels have been selected. I think that should put a lot of the unknowns to bed and investors can take a view based on the facts rather than opinion ...

Don't take any advice from anyone, there are no multimillionaires having had great success in their own investment strategies posting on these boards...

We've been constantly saying that no news is no news, nothing material to report and I suspect if approvals are still not in all David can say is the commercialisation that is lined up is contingent on those approvals coming in.... they will of course and the demand will still be there but there is a lot of impatience when holders see other stocks doing well. We will have our day, I appreciate the integrity of the Genedrive BODs...

Samuel - it was a difficult week for all the UK COVID companies wrt share prices last week. An overreaction I think personally.

We release news when there are things to say or report, but have never released news based on fluff (as some companies do). That's just our choice. So silence really means "nothing to say". We'll always disclose material information. We would have hoped to have a more continuous newsflow but it hasn't happened in that way.

You are always welcome to contact me if you have questions, or alternatively our Financial PR Company Walbrook. https://www.walbrookpr.com I receive many incoming requests for information. Some are thoughtful, inciteful, and genuinely inquisitive. I try when I can to reply to those. Others are from people that aren't very professional in their attitudes or questions, and I don't reply to many of those. As a public company, I just cant answer every questions, and I know that's frustrating for some people.

There is an investor presentation next Wednesday via Investor Meet Company, and there is an opportunity to submit a question in advance.

David Budd

Try, I agree, the AIHL can prevent a lot of profound deafness related to gentamicin, Genedrive provides a compelling solution at POC. Other tests can then roll out on that installed platform base.

I agree too, we don't yet have a vaccine, when we do we are 12 months away from not needing mass testing in the west, probably a lot longer in other countries who won't have access to the vaccine. It is highly possible the vaccine is only short-lived if the virus behaves in a similar way to influenza and the common cold which is another coronavirus....

Thanks longterm, I always think it's better to have passion for success than passion for failure, and I know here we will make a difference. We'll bite our tongue and raise a glass to success in the coming weeks and months knowing we held firm because success is not measured in £'s but in a life saved. I know for example that many people will have been tested in India using our tests to build up confidence that the test works and in supporting the approvals process. The same in the US looking saliva and here in the UK with the POC test thats undergoing it's approvals. All these add confidence in the business. I also know these are gold standard tests.

Hopefully next week DB will be able to talk about the Company's strategy to investors. GDR are not a customer facing business, they don't have that level of technical support, so I suspect they want to partner B2C businesses like BC in order to supply 'systems' that pull together key strengths to provide something more compelling than the test itself.

Without doubt the speed of approvals has been painful. But be in no doubt, this time next year we will still need testing regardless of whether there's a vaccine thats effective and effective for periods of longer than a few months. The Pfizer vaccine only stopped symptoms, there is no data on whether it prevented infection or prevents people from passing on the virus. The clinical trial was woeful and biased only to demonstrate the minimum - that there was a reduction in the number of people displaying symptoms. No data on whether testing was done to show the level of asymptomatic people... just a word of caution about how the data has been presented and what's not been shown!

Cheers Chelmo, its good to know there are some proper 'investors' here

When it hit 300p the number of shares were significantly lower. The current market cap clearly has no COVID sentiment built in, shown even more so since the so called Covid bubble burst. Now is the time for people who do have faith that the product is right, services many markets, and is desperately needed. One child with saved hearing, one person diagnosed with HCV so they can go on treatment and be saved, one person diagnosed with Tb, thats the ultimate goal. Genedrive is a cracking product, innovation takes time and costs, but they have and continue to make a lot of progress. Ultimately it will be a larger company the makes the most from this, but I do know the current market cap doesn't reflect the value, it reflects the sentiment - some driven by greed.

It’s down to sensitivity, either the test is not sensitive enough (non-PCR tests are not as sensitive as PCR) or the patient had a low level infection (if the virus isn’t in the sample each time you won’t detect it). All of the antibody or antigen based tests other than PCR are insensitive, they always have been, it’s why PCR is the gold standard...

I have been a holder here a for a while. I invested because the products this company makes has a real potential to save lives. Apart from their COVID test which is awaiting approvals in key markets they have large partners for, they are making a POC system. They have successfully made tests for HCV and antibiotic induced hearing loss which affects 1 in 500 children given gentamicin. The will profoundly benefit a large number of people. I don’t give carp what the trollers here say, or if the share price drops further because people are selling COVID stocks to buy cinema and airline stocks. I want the company to succeed because, as COVID has shown, it’s the right product and the world needs it....

Best to simply ignore bullies and starve them of responses

Hi Ct, good to see you back! I agree, if someone is not invested and is only posting to talk a share dow, then they’re simply trolling - not nice. Legitimate concerns are important to talk about openly, same about strategy. But calling into question the integrity, capability or the character of the CEO is disrespectful and doesn’t reflect informed discussion.